Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
Yang JC, Han B, De La Mora Jiménez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csőszi T.
Yang JC, et al. Among authors: zimmer z.
J Thorac Oncol. 2023 Dec 29:S1556-0864(23)02432-2. doi: 10.1016/j.jtho.2023.12.023. Online ahead of print.
J Thorac Oncol. 2023.
PMID: 38159809
Free article.